scholarly journals Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation

2012 ◽  
Vol 87 (4) ◽  
pp. 392-400 ◽  
Author(s):  
Chia Chi Sun ◽  
Valentina Vaja ◽  
Jodie L. Babitt ◽  
Herbert Y. Lin
Keyword(s):  
Chronic Disease ◽  
Treatment Strategies ◽  
Anemia Of Chronic Disease ◽  
New Treatment ◽  
Anemia Of Inflammation

Anemia of Chronic Disease (Anemia of Inflammation)

2009 ◽  
Vol 122 (2-3) ◽  
pp. 103-108 ◽  
Author(s):  
Neeraj Agarwal ◽  
Josef T. Prchal
Keyword(s):  
Chronic Disease ◽  
Anemia Of Chronic Disease ◽  
Anemia Of Inflammation

Anemia: Production Defects Generally Associated with a Normal or Largely Normal Bone Marrow

2017 ◽  
Author(s):  
Nancy Berliner ◽  
John M Gansner
Keyword(s):  
Bone Marrow ◽  
Differential Diagnosis ◽  
Chronic Disease ◽  
Blood Cells ◽  
Deficiency Anemia ◽  
Normal Bone Marrow ◽  
Peripheral Smear ◽  
Anemia Of Chronic Disease ◽  
Normal Bone ◽  
Anemia Of Inflammation

This review focuses on anemia resulting from production defects generally associated with a normal or largely normal bone marrow. The definition, epidemiology, etiology, pathogenesis, diagnosis, differential diagnosis, management, complications, and prognosis of the following production defects are discussed: Anemia of inflammation (AI; formerly known as anemia of chronic disease), and anemia in kidney disease, as well as anemia secondary to other conditions such as alchohol abuse and starvation. Iron deficiency anemia (IDA) is discussed elsewhere in this publication.  A figure depicts peripheral smear changes in the size and shape of red blood cells seen in starvation. A table lists the differential diagnoses of hypochromic anemias. This review contains 1 figure; 1 table; 79 references

scholarly journals Serum Hepcidin: A Direct Link Between Anemia of Inflammation and Coronary Artery Atherosclerosis in Patients with Rheumatoid Arthritis

2011 ◽  
Vol 38 (10) ◽  
pp. 2153-2159 ◽  
Author(s):  
MANAL ALY ABDEL-KHALEK ◽  
AMAL MOHAMAD EL-BARBARY ◽  
SALWA ABDEL-MONEIM ESSA ◽  
ABEER SAEED GHOBASHI
Keyword(s):  
Rheumatoid Arthritis ◽  
Chronic Disease ◽  
Coronary Artery ◽  
Disease Activity ◽  
Deficiency Anemia ◽  
Anemia Of Chronic Disease ◽  
Coronary Artery Atherosclerosis ◽  
Serum Hepcidin ◽  
Index Value ◽  
Anemia Of Inflammation

Objective.To investigate the role of hepcidin as an inducer of anemia of inflammation in patients with rheumatoid arthritis (RA), and its correlation to coronary artery atherosclerosis.Methods.Our study included 60 patients with RA and 20 healthy controls. Anemic RA patients with serum transferrin receptors/log ferritin (sTfR-F) index value < 1.5 were classified as having pure anemia of chronic disease (ACD), and patients with sTfR-F index value > 1.5 were classified as having anemia of chronic disease with coexistent iron deficiency anemia (ACD+IDA). Measurements were taken for Disease Activity Score for 28 joints (DAS28), Modified Health Assessment Questionnaire (MHAQ), erythrocyte sedimentation rate (ESR), high sensitivity C-reactive protein (hsCRP), rheumatoid factor (RF), lipid profile, serum interleukin 6 (IL-6), tumor necrosis factor-α, iron studies, and serum hepcidin. Coronary calcium score (CCS) was measured using multislice spiral computed tomography as a marker of atherosclerosis.Results.Serum hepcidin was found to be higher in anemic patients with RA than in controls (p < 0.001), and higher in the pure ACD subgroup than in the ACD+IDA subgroup (p < 0.001). Hepcidin concentration was positively correlated with disease duration, ESR, hsCRP, RF, DAS28, MHAQ, serum ferritin, IL-6, and mean CCS and inversely correlated with hemoglobin, sTfR, and the sTfR-F index.Conclusion.Hepcidin can be considered a key inducer of anemia of inflammation in patients with RA. This inflammation was proved to be directly linked to coronary artery atherosclerosis. The correlations between serum hepcidin with disease activity and IL-6 raise the possibility of using it as a surrogate marker for disease activity.

Anemia: Production Defects Generally Associated with a Normal or Largely Normal Bone Marrow

2017 ◽  
Author(s):  
Nancy Berliner ◽  
John M Gansner
Keyword(s):  
Bone Marrow ◽  
Differential Diagnosis ◽  
Chronic Disease ◽  
Blood Cells ◽  
Deficiency Anemia ◽  
Normal Bone Marrow ◽  
Peripheral Smear ◽  
Anemia Of Chronic Disease ◽  
Normal Bone ◽  
Anemia Of Inflammation

This review focuses on anemia resulting from production defects generally associated with a normal or largely normal bone marrow. The definition, epidemiology, etiology, pathogenesis, diagnosis, differential diagnosis, management, complications, and prognosis of the following production defects are discussed: Anemia of inflammation (AI; formerly known as anemia of chronic disease), and anemia in kidney disease, as well as anemia secondary to other conditions such as alchohol abuse and starvation. Iron deficiency anemia (IDA) is discussed elsewhere in this publication.  A figure depicts peripheral smear changes in the size and shape of red blood cells seen in starvation. A table lists the differential diagnoses of hypochromic anemias. This review contains 1 figure; 1 table; 79 references

Herpesvirus infection as one of the causes of anemia

2019 ◽  
Vol 24 (2) ◽  
pp. 161-166 ◽  
Author(s):  
О. A. Uspenskaya ◽  
S. A. Spiridonova
Keyword(s):  
Chronic Disease ◽  
Viral Infection ◽  
Binding Capacity ◽  
Herpesvirus Infection ◽  
Hemoglobin Content ◽  
Anemia Of Chronic Disease ◽  
Tnf Α ◽  
Iron Binding Capacity ◽  
Timely Treatment ◽  
Average Hemoglobin

Relevance. One of the causes of chronic disease is herpetic infection, lifelong persistence in the human body and activates the macrophage protection system, which leads to disruption of iron utilization by the cells of the hematopoietic system and the development of anemia of chronic disease. To prove the influence of herpesvirus infection on the occurrence of anemia of chronic disease.Materials and methods. The study involved 75 people suffering from herpes-viral infection. 3 groups were allocated: the frst group (25 people) received acyclovir 1 tablet (200 mg) 5 times a day, 5 days; The 2-nd group (25 people) used famvir for 1 tablet (250 mg) 2 times a day, 5 days; The third group (25 people) – famvir 1 tablet (250 mg) 2 times a day, 5 days and kagocel 2 tablets (12 mg) 3 times a day, 5 days.Result. All subjects examined at the time of treatment showed an increase in the content of IL 1β mRNK and TNF-α and a decrease in mRNK of IL 8 and IL 10; on day 14 of the study, a decrease in IL 1β mRNK and TNF-α mRNK and an increase in IL 10 mRNK. In the study of erythrocyte indices – the average volume of erythrocytes and the average hemoglobin content in erythrocyte and the parameters of iron-serum iron metabolism and the total iron binding capacity of the serum, slight deviations from the norm were obtained.Conclusions. Thus, we concluded that the cause of anemia, in addition to the lack of iron, can be chronic herpesvirus infection, and thus timely treatment of a viral infection excludes the use of ferrotherapy.

Humoral Immunity in Heart Failure

2019 ◽  
Vol 19 (1) ◽  
pp. 14-18 ◽  
Author(s):  
Amrita Sarkar ◽  
Khadija Rafiq
Keyword(s):  
Heart Failure ◽  
Humoral Immunity ◽  
Treatment Strategies ◽  
Pathophysiological Mechanism ◽  
Peripheral Vascular ◽  
Cardiac Inflammation ◽  
Humoral Immune ◽  
Humoral Immune System ◽  
New Treatment ◽  
Immunity Function

Cardiovascular Disease (CVD) is a class of diseases that involve disorders of heart and blood vessels, including hypertension, coronary heart disease, cerebrovascular disease, peripheral vascular disease, which finally lead to Heart Failure (HF). There are several treatments available all over the world, but still, CVD and heart failure became the number one problem causing death every year worldwide. Both experimental and clinical studies have shown a role for inflammation in the pathogenesis of heart failure. This seems related to an imbalance between pro-inflammatory and anti-inflammatory cytokines. Cardiac inflammation is a major pathophysiological mechanism operating in the failing heart, regardless of HF aetiology. Disturbances of the cellular and humoral immune system are frequently observed in heart failure. This review describes how B-cells play a specific role in the heart failure states. There is an urgent need to identify novel therapeutic targets and develop advanced therapeutic strategies to combat the syndrome of HF. Understanding and describing the elements of the humoral immunity function are essential and may suggest potential new treatment strategies.

scholarly journals Emerging Natural-Product-Based Treatments for the Management of Osteoarthritis

Antioxidants ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 265
Author(s):  
Maria-Luisa Pérez-Lozano ◽  
Annabelle Cesaro ◽  
Marija Mazor ◽  
Eric Esteve ◽  
Sabine Berteina-Raboin ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Natural Product ◽  
Treatment Strategies ◽  
Cartilage Degradation ◽  
Therapeutic Strategies ◽  
Clinical Models ◽  
Osteoarthritic Joint ◽  
Dietary Components ◽  
New Treatment ◽  
Review Current

Osteoarthritis (OA) is a complex degenerative disease in which joint homeostasis is disrupted, leading to synovial inflammation, cartilage degradation, subchondral bone remodeling, and resulting in pain and joint disability. Yet, the development of new treatment strategies to restore the equilibrium of the osteoarthritic joint remains a challenge. Numerous studies have revealed that dietary components and/or natural products have anti-inflammatory, antioxidant, anti-bone-resorption, and anabolic potential and have received much attention toward the development of new therapeutic strategies for OA treatment. In the present review, we provide an overview of current and emerging natural-product-based research treatments for OA management by drawing attention to experimental, pre-clinical, and clinical models. Herein, we review current and emerging natural-product-based research treatments for OA management.

Sign in / Sign up

Export Citation Format

Share Document